Researchers identify molecular cause of drug-resistant prostate cancer
A team of researchers identified a molecular mechanism driving drug resistance in prostate cancer, revealing that hormone-refractory cells develop an altered androgen receptor. The findings suggest that even low levels of testosterone can activate these receptors, leading to the conversion of anti-androgen drugs into agonist drugs.